Bioalliance C.v.

Academia Sinica

Abgenomics International Inc.

Shu-Hua Lee

Shih-Yao Lin

Rong-Hwa Lin

Leewen Lin

Lie-Fen Shyur

Chiu-Chen Huang

Ning-Sun Yang

Yu-Ying Tsai

Yu-Chi Hsieh

Feng-Lin Chiang

Li-An Hu

Tuan-Nan Wen

The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.

Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof

The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lestructure, a Le-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same

A truncated 1,3-1,4-&#x3b2;-D-glucanase. Also disclosed are related nucleic acid, vector, host cell, and preparation method.

Truncated 1,3-1,4-&#x3b2;-D-glucanase

Growing community of inventors

Taipei, Taiwan

Shu-Hua Lee